Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

Cancer statistics, 2013

(2013) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

(2012) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma

(2011) Kevin B. Kim et al.   JOURNAL OF CLINICAL ONCOLOGY

Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006

(2011) Ahmedin Jemal et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity

(2010) J-M Lee et al.   BRITISH JOURNAL OF CANCER

Circulating biomarkers of bevacizumab activity in patients with breast cancer

(2010) Neelima Denduluri et al.   CANCER BIOLOGY & THERAPY

mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor

(2009) H. A. Lane et al.   CLINICAL CANCER RESEARCH

9172 Analysis of biomarkers (BMs) in the AVAiL phase III randomised study of first-line Bevacizumab (Bv) with cisplatin-gemcitabine (CG) in patients (pts) with non-small cell lung cancer (NSCLC)

(2009) N. Leighl et al.   EJC SUPPLEMENTS

Final Version of 2009 AJCC Melanoma Staging and Classification

(2009) Charles M. Balch et al.   JOURNAL OF CLINICAL ONCOLOGY

Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

(2008) Nilofer S. Azad et al.   JOURNAL OF CLINICAL ONCOLOGY